HK1198920A1 - Method of treating a proliferative disease - Google Patents

Method of treating a proliferative disease

Info

Publication number
HK1198920A1
HK1198920A1 HK14112437.0A HK14112437A HK1198920A1 HK 1198920 A1 HK1198920 A1 HK 1198920A1 HK 14112437 A HK14112437 A HK 14112437A HK 1198920 A1 HK1198920 A1 HK 1198920A1
Authority
HK
Hong Kong
Prior art keywords
treating
proliferative disease
proliferative
disease
Prior art date
Application number
HK14112437.0A
Other languages
English (en)
Chinese (zh)
Inventor
Darrin Stuart
Meghna Das Thakur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1198920A1 publication Critical patent/HK1198920A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14112437.0A 2011-11-11 2014-12-10 Method of treating a proliferative disease HK1198920A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558619P 2011-11-11 2011-11-11
PCT/US2012/064269 WO2013070996A1 (en) 2011-11-11 2012-11-09 Method of treating a proliferative disease

Publications (1)

Publication Number Publication Date
HK1198920A1 true HK1198920A1 (en) 2015-06-19

Family

ID=47279036

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112437.0A HK1198920A1 (en) 2011-11-11 2014-12-10 Method of treating a proliferative disease

Country Status (11)

Country Link
US (1) US11007194B2 (fi)
EP (1) EP2776037B1 (fi)
JP (1) JP6150813B2 (fi)
CN (2) CN103917236A (fi)
AU (1) AU2012335663B2 (fi)
BR (1) BR112014011223A8 (fi)
CA (1) CA2855243C (fi)
HK (1) HK1198920A1 (fi)
MX (1) MX354725B (fi)
RU (1) RU2622015C2 (fi)
WO (1) WO2013070996A1 (fi)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
NZ703940A (en) * 2012-08-07 2018-04-27 Novartis Ag Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
SG11201810793XA (en) * 2016-06-03 2018-12-28 Giordano Caponigro Pharmaceutical combinations
US11590133B2 (en) * 2016-12-11 2023-02-28 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of BRAF mutant cancers
US20210283132A1 (en) * 2018-07-12 2021-09-16 Shenzhen Targetrx, Inc. Diarylpyrazole compound, composition comprising same, and use thereof
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1000055A1 (en) 1997-05-22 2000-05-17 G.D. Searle & Co. SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2005506366A (ja) 2001-10-25 2005-03-03 ノバルティス アクチエンゲゼルシャフト 選択的シクロオキシゲナーゼ−２阻害剤を含む組合せ剤
WO2003055860A1 (en) 2001-12-21 2003-07-10 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
JP2007505938A (ja) 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
DK1692113T3 (en) 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
EP1706400A1 (en) 2004-01-09 2006-10-04 Novartis AG Phenyl- 4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl -amine derivatives as igf-ir inhibitors
ES2396135T3 (es) 2004-06-10 2013-02-19 Irm Llc Compuestos y composiciones como inhibidores de proteínas cinasas
RU2007138264A (ru) 2005-03-17 2009-09-10 Новартис АГ (CH) N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF
US20070099856A1 (en) * 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
AU2006279794B2 (en) 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
CN102198273A (zh) 2005-08-22 2011-09-28 诺瓦提斯公司 包含pH依赖性药物、pH调节剂和阻滞剂的药物组合物
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
JP2009530261A (ja) 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク ピラゾール化合物
CN101415411A (zh) 2006-04-05 2009-04-22 诺瓦提斯公司 用于治疗癌症的治疗剂组合
US7501430B2 (en) 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
WO2008042639A1 (en) 2006-10-02 2008-04-10 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0717805A2 (pt) 2006-10-06 2013-10-29 Irm Llc Inibidores de proteína quinase e métodos de uso dos mesmos
RU2009134223A (ru) 2007-02-15 2011-03-20 Новартис АГ (CH) Комбинация lbh589 с другими терапевтическими средствами, предназначенная для лечения рака
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
BRPI0815042A2 (pt) 2007-08-01 2015-02-10 Pfizer Compostos de pirazol
RU2010119929A (ru) 2007-10-19 2011-11-27 Эбботт Гмбх Унд Ко.Кг (De) Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
KR101408517B1 (ko) 2008-03-21 2014-06-17 노파르티스 아게 신규한 헤테로시클릭 화합물 및 그의 용도
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102105459B (zh) 2008-07-24 2014-09-10 内尔维阿诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑类
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
JP5603869B2 (ja) 2008-09-29 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
WO2010056662A1 (en) 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
WO2010070060A1 (en) 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) * 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
WO2010145998A1 (en) 2009-06-15 2010-12-23 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
JP5806239B2 (ja) 2010-01-27 2015-11-10 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ プロテインキナーゼ阻害剤としての３，４−ジアリールピラゾールのスルホンアミド誘導体
KR101955691B1 (ko) 2010-03-30 2019-03-07 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
WO2012016993A1 (en) 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
US20140093565A1 (en) 2011-03-21 2014-04-03 Valcuria Ab A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof
MX344580B (es) 2011-06-14 2016-12-20 Novartis Ag Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa.
MY172729A (en) 2011-11-23 2019-12-11 Array Biopharma Inc Pharmaceutical formulations
RU2015121367A (ru) 2012-11-08 2017-01-10 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний

Also Published As

Publication number Publication date
WO2013070996A1 (en) 2013-05-16
CN103917236A (zh) 2014-07-09
RU2622015C2 (ru) 2017-06-08
CA2855243A1 (en) 2013-05-16
MX354725B (es) 2018-03-16
US11007194B2 (en) 2021-05-18
EP2776037B1 (en) 2019-01-09
EP2776037A1 (en) 2014-09-17
CA2855243C (en) 2020-04-14
US20140275136A1 (en) 2014-09-18
RU2014117707A (ru) 2015-12-20
BR112014011223A2 (pt) 2017-05-09
JP6150813B2 (ja) 2017-06-21
MX2014005726A (es) 2014-05-28
AU2012335663B2 (en) 2015-12-24
JP2014533272A (ja) 2014-12-11
AU2012335663A1 (en) 2014-05-29
CN108542906A (zh) 2018-09-18
BR112014011223A8 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
EP2773754A4 (en) Methods of Treatment
GB201110095D0 (en) Method of treatment
PL2685961T3 (pl) Sposób leczenia urazu neurologicznego
HK1201040A1 (en) Method for treating osteoporosis
ZA201208219B (en) Method for treating wasterwater
HK1198920A1 (en) Method of treating a proliferative disease
HK1199261A1 (en) Methods for treatment of diseases
EP2701694A4 (en) METHOD FOR THE TREATMENT OF HEMOGLOBINOPATHIES
IL228917A0 (en) Methods for treating solid tumors
GB201302929D0 (en) A method of treating alzheimers disease
IL232493A0 (en) A method for quantifying cancer treatment
HRP20181649T1 (hr) Metoda liječenja osteoporoze
GB201112696D0 (en) A method of treating an aerofoil
EP2705098A4 (en) METHOD FOR MODIFYING THE SURFACE OF A BODY
EP2723348A4 (en) METHOD FOR THE TREATMENT OF ADIPOSITAS
GB201108797D0 (en) Surface treatment method
IL229552A (en) A method of applying pressure to a material
PL2694094T3 (pl) Sposób leczenia stanów związanych z IFNalfa
GB201121950D0 (en) Treatment process
GB201105523D0 (en) Treatment method
ZA201400716B (en) A method for the treatment of hair
EP2791324A4 (en) PROCESSING METHOD
GB201114721D0 (en) Method of treating a material
GB201113086D0 (en) Method of treating a material
GB201111530D0 (en) Method of treatment